| Execution period | 3 months |
|---|
NSE filing, NSE: COCHINSHIP. Summary written from the filing by ALFA Finder's alert engine.
Cochin Shipyard Ltd: key numbers
- Share price
- ₹1,129.90
- Market cap
- ₹29,726 Cr
- Revenue (annual)
- ₹5,022 Cr
- Net profit (annual)
- ₹716.7 Cr
- P/E (TTM)
- 43.7×Sector 30.1×
- Promoter holding
- 63.33%-4.58% QoQ
- FII holding
- 3.07%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Cochin Shipyard Ltd
All →Cochin Shipyard Other Announcement
Cochin Shipyard Limited received unsolicited ESG ratings from CRISIL ESG Ratings & Analytics. The company was assigned a 'CRISIL ESG 59' score and a 'CRISIL Core ESG 66' rating.
Cochin Shipyard Bags ₹250 Cr Order from Heritage River Journeys Private Limited
Cochin Shipyard Ltd's subsidiary, Hooghly Cochin Shipyard, secured a Rs.250 Crore order from Heritage River Journeys to construct two luxury river cruise vessels by 2030.
- Value
- ₹250.0 Cr
- From
- Heritage River Journeys Private Limited
- Execution
- June 2029 and June 2030
- Luxury River Cruise vessels
- 2.0 vessels
Cochin Shipyard Price Movement Clarification
Cochin Shipyard clarified that media reports regarding a 40-ship order from multiple nations are unverified. The company confirmed it has no further firm orders beyond those already disclosed.
Cochin Shipyard Bags ₹100 Cr Order from Heritage River Journeys Private Limited
Cochin Shipyard's subsidiary, Hooghly-CSL, secured a 'Notable' order from Heritage River Journeys for two luxury river cruise vessels. The contract value is between ₹100 Crore and ₹250 Crore.
- Value
- ₹100.0 Cr
- From
- Heritage River Journeys Private Limited
- Execution
- By June 2030
- luxury river cruise vessels
- 2.0 vessels
Cochin Shipyard Debt & Borrowing
Cochin Shipyard Ltd filed its half-yearly ISIN statement for debt securities as on September 30, 2026. One NCD of ₹23 Crore maturing March 2029 remains outstanding.
Cochin Shipyard Annual General Meeting
Cochin Shipyard seeks shareholder approval to transfer its ISRF to a 50:50 JV with Drydocks World–Dubai at Rs. 1,800 Crore. E-voting closes November 7, 2026.
- Value
- ₹1,800 Cr
Other regulatory approval announcements
All →Shalby Regulatory Approval
Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.
Elantas Beck India Regulatory Approval
Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.
Kalyani Cast-Tech Regulatory Approval
Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.
Mukka Proteins Regulatory Approval
Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.
- Execution
- October 1, 2026 to December 31, 2027
Canara Bank Regulatory Approval
Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.
- Value
- ₹1,500 Cr
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.